Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 1 hour 1 min ago

Coherus BioSciences Secures $55 million Series C Financing

Mon, 05/19/2014 - 12:12
REDWOOD CITY, Calif., May 19, 2014 -- (Healthcare Sales & Marketing Network) -- Coherus BioSciences, Inc. ("Coherus"), a leading biologics platform company focused on biosimilars, announced today the closing of a Series C Preferred investment ro...
Biopharmaceuticals, Venture Capital
Coherus Biosciences, biosimilar

Biocept Announces National Sales Force

Mon, 05/19/2014 - 12:06
Oncology Sales Specialists to Deploy Blood-Based Cancer Diagnostics Into Physician Practices and Pharmaceutical Development Markets SAN DIEGO, May 19, 2014 -- (Healthcare Sales & Marketing Network) -- Biocept, Inc. (BIOC), a molecular oncology diagnosti...
Diagnostics, Oncology
Biocept, OncoCEE, Circulating Tumor Cells

Ventrus Biosciences to Merge With Assembly Pharmaceuticals

Mon, 05/19/2014 - 12:00
New Company, Assembly Biosciences, to Focus on First-in Class Technology for Treatment and Potential Cure of Hepatitis B Virus Infection, Affecting 350 Million Worldwide Projected Multi-Billion Market Opportunity; No Curative Therapy Exists Combined ...
Biopharmaceuticals, Mergers & Acquisitions
Ventrus Biosciences, Assembly Pharmaceuticals, Hepatitis B

Genkyotex Announces New Senior Management and Board Appointments

Mon, 05/19/2014 - 11:50
GENEVA & ARCHAMPS, France--(Healthcare Sales & Marketing Network)--Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today the appointment of Dr. Jeanette Wood as Chief Scientific Officer and Dr. Joseph McCracken to the Board o...
Biopharmaceuticals, Personnel
Genkyotex, GKT137831, NOX inhibitors

Shire Plans to Submit a New Drug Application to FDA for Lifitegrast for Dry Eye Disease in Adults

Mon, 05/19/2014 - 11:45
FDA submission planned for 1st Quarter 2015 Shire forms business unit focused in ophthalmics LEXINGTON, Massachusetts, May 19, 2014 -- (Healthcare Sales & Marketing Network) -- Following a May 15, 2014, meeting with the U.S. Food and Drug Administra...
Biopharmaceuticals, Ophthalmology
Shire plc, dry eye disease, Lifitegrast

OXiGENE Names Experienced Biotech Executive, David J. Chaplin, Ph.D., as President and Chief Executive Officer

Fri, 05/16/2014 - 14:26
SOUTH SAN FRANCISCO, Calif., May 16, 2014 -- (Healthcare Sales & Marketing Network) -- OXiGENE, Inc. (OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that David (Dai) Chaplin, Ph.D., has been appoi...
Biopharmaceuticals, Oncology, Personnel
OXiGENE, vascular disrupting agents

Proteon Therapeutics Announces $45 Million of Series D Financing

Fri, 05/16/2014 - 14:24
Company Poised to Initiate Phase 3 Trial of PRT-201 for Reduction of AVF Failure in Hemodialysis WALTHAM, Mass.--(Healthcare Sales & Marketing Network)--Proteon Therapeutics Inc., a privately held biopharmaceutical company developing novel, first-in-cla...
Biopharmaceuticals, Venture Capital
Proteon Therapeutics, Elastase, hemodialysis, vascular access

Sorbent Therapeutics Closes First Tranche Of $15 Million Series D Financing

Thu, 05/15/2014 - 15:05
Completes Enrollment in Phase 2b Clinical Trial of CLP-1001 for Heart Failure SUNNYVALE, Calif., May 15, 2014 -- (Healthcare Sales & Marketing Network) -- Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular a...
Biopharmaceuticals, Cardiology, Venture Capital
Sorbent Therapeutics, Heart Failure

Boston Scientific Announces Definitive Agreement To Acquire Interventional Division Of Bayer AG

Thu, 05/15/2014 - 15:01
Acquisition Expected to Strengthen Peripheral Interventions Business and Accelerate Growth in Peripheral Atherectomy and Thrombectomy Categories NATICK, Mass., May 15, 2014 -- (Healthcare Sales & Marketing Network) -- In a move to expand significantly ...
Devices, Interventional, Acquisitions
Boston Scientific, Bayer AG, Bayer Interventional, AngioJet, Thrombectomy

TERUMO(R) Launches Expanded GLIDEWAY(TM) Access Sheath Portfolio With A New Product For Minimally Invasive Urologic Procedures

Thu, 05/15/2014 - 14:25
New GLIDEWAY™ Ureteral Access Sheath Offers Advanced Features Designed to Minimize Trauma SOMERSET, N.J., May 15, 2014 -- (Healthcare Sales & Marketing Network) -- TERUMO, a leading global medical device company, today announced the U.S. launch of its ...
Devices, Interventional, Urology, Product Launch
Terumo Medical, GLIDEWAY, Access Sheath, nephrolithotomy, ureteroscopy

John D. Thompson Joins Transgenomic's Board of Directors

Thu, 05/15/2014 - 14:21
OMAHA, Neb.--(Healthcare Sales & Marketing Network)--Transgenomic, Inc. (TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research servi...
Diagnostics, Personalized Medicine, Personnel
Transgenomic, ICE COLD-PCR

Mylan Applauds Court's Ruling Dismissing Teva's Suit Against FDA on Copaxone(R)

Thu, 05/15/2014 - 14:18
PITTSBURGH, May 15, 2014 -- (Healthcare Sales & Marketing Network) -- Mylan Inc. (MYL) today commented on the ruling by the U.S. District Court for the District of Columbia against Teva in their suit against the U.S. Food and Drug Administration (FDA), wh...
Biopharmaceuticals, Generics, FDA, Litigation
Mylan, Teva Pharmaceutical, Copaxone

Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer

Wed, 05/14/2014 - 12:57
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Agios Pharmaceuticals, Inc. (AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), today announced the appointment of Chris Bowden, M.D., to the newly created po...
Biopharmaceuticals, Personnel
Agios Pharmaceuticals

POZEN Announces U.S. Rights for Treximet(R) to Be Acquired by Pernix Therapeutics

Wed, 05/14/2014 - 12:48
POZEN to Receive Pernix Warrants and ROW Rights to Treximet CHAPEL HILL, N.C.--(Healthcare Sales & Marketing Network)--POZEN Inc. (POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that GlaxoSmithK...
Biopharmaceuticals, Acquisitions
POZEN, GlaxoSmithKline, Pernix Therapeutics, Treximet

Acorda Therapeutics Appoints Andrew Hindman as Chief Business Development Officer

Wed, 05/14/2014 - 12:42
Company also announces Soon Hyouk Lee as its new Vice President of Business Development ARDSLEY, N.Y.--(Healthcare Sales & Marketing Network)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) has appointed Andrew Hindman as Chief Business Development Officer. ...
Biopharmaceuticals, Personnel
Acorda Therapeutics

Acorda Therapeutics Appoints Andrew Hindman as Chief Business Development Officer

Wed, 05/14/2014 - 12:41
Company also announces Soon Hyouk Lee as its new Vice President of Business Development ARDSLEY, N.Y.--(Healthcare Sales & Marketing Network)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) has appointed Andrew Hindman as Chief Business Development Officer. ...
Biopharmaceuticals, Personnel
Acorda Therapeutics

Medrobotics Closes $26 Million Series E Financing

Wed, 05/14/2014 - 12:31
Company Prepares for European Commercialization of the Ground-Breaking Flex® System in Otolaryngology RAYNHAM, Mass.--(Healthcare Sales & Marketing Network)--Medrobotics Corp., a surgical products company with core competencies in medical robotics,...
Devices, Surgery, Venture Capital
Medrobotics, Flex System, robotic-assist platform, endoscopic, robotic surgery

Senior Level Changes at Dr. Reddy’s

Wed, 05/14/2014 - 12:22
HYDERABAD, India--(Healthcare Sales & Marketing Network)--Dr. Reddy’s Laboratories Ltd. (RDY) today announced that its Board of Directors has decided to have separate roles of the Chairman of the Company and the Managing Director and CEO. It has appoint...
Biopharmaceuticals, Personnel
Dr. Reddy’s Laboratories

Avedro Welcomes Robert J. Palmisano to its Board of Directors

Wed, 05/14/2014 - 12:17
Seasoned Veteran in Value Creation for Ophthalmic Medical Device Companies WALTHAM, Mass.--(Healthcare Sales & Marketing Network)--Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company announces today that Robert J. Palmisano ...
Devices, Ophthalmology, Personnel
Avedro, KXL System

Gemmus Pharma Closes $3.3M Series B Funding to Develop Superior Flu Drug

Tue, 05/13/2014 - 14:55
Company Presenting at 27th Annual International Society for Antiviral Research (ISAR) on Specific Isomer SAN FRANCISCO--(Healthcare Sales & Marketing Network)--Gemmus Pharma Inc. a privately held biotechnology company developing an improved host-targete...
Biopharmaceuticals, Venture Capital
Gemmus Pharma, influenza

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong